Collaborations, Licensing and Other Arrangements (Tables)

3 Months Ended

Mar. 31, 2025

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Schedule of Total Revenue from Collaboration and Services

Revenue from collaborations and services were as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
UT CSA(1)	$	28,818	$	24,464
Amphastar co-promotion agreement		500		—
Cipla License and Distribution Agreement		36		37
Other		22		—
UT License Agreement		—		347
Total revenue from collaborations and services	$	29,376	$	24,848

_________________________

(1)Amounts consist of revenue recognized for Manufacturing Services to UT for the periods presented.

United Therapeutics Corporation

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Schedule of Total Revenue from Collaboration and Services

Total revenue from UT was as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
Revenue from UT
Royalties(1)	$	30,005	$	22,651
UT CSA		28,818		24,464
UT License Agreement		—		347
Total revenue from UT	$	58,823	$	47,462

_________________________

(1)Amounts consist of royalties associated with the UT License Agreement. The contract assets related to the royalties is included in prepaid expense and other current assets in the condensed consolidated balance sheets.